Arcutis’ ZORYV. FDA OK for Plaque Psoriasis

 

• Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of use
• More than half of the nearly 9 million people in the United States with plaque psoriasis experience scalp involvement
• Healthcare providers and individuals with plaque psoriasis can now choose ZORYVE foam or cream to treat plaque psoriasis anywhere it appears on the body
• Fifth FDA approval for ZORYVE in less than three years
• Management will host an investor event with a key opinion leader on Monday, June 2 at 8:00 am ET/5:00 am PT

https://www.streetinsider.com/Globe+Newswire/Arcutis%E2%80%99+ZORYVE%C2%AE+%28roflumilast%29+Topical+Foam+0.3%25+Approved+by+U.S.+FDA+for+the+Treatment+of+Plaque+Psoriasis+in+Adults+and+Adolescents+Ages+12+and+Older/24839826.html